Effects of Pomegranate Seed Oil Supplementation in Patients With Advanced Dementia

Effects of a Twenty-Four-Week Pomegranate Seed Oil Supplementation in Palliative Care Patients With Advanced Dementia: A Double Blind, Randomized Controlled Clinical Study

The goal of this clinical study is to learn if Pomegranate Seed Oil supplementation works to combat urinary tract infections, recurrenturinary tract infections, or pneumonia and contributes to the tapering or discontinuation of antipsychotics in palliative care patients withadvanced dementia.

The main questions it aims to answer are:

• Does Pomegranate Seed Oil supplementation reduce the likelihood of developing a urinary tract infection?
• Does Pomegranate Seed Oil supplementation prevent UTI reinfection?
• Does Pomegranate Seed Oil supplementation reduce the likelihood of pneumonia?
• Does Pomegranate Seed Oil supplementation contribute to the tapering or discontinuation of antipsychotics?

Researchers will compare Pomegranate Seed Oil to care-as-usual to see if Pomegranate Seed Oil supplementation can increase quality of care in palliative care patients with advanced dementia.

Inclusion Criteria:

• Aged 65+
• Dementia diagnosis (major neurocognitive disorder) according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
• Participants classified as Stage 7, Profound Cognitive Decline on the Global Deterioration Scale, corresponding to advanced dementia
• AD related biomarkers in CSF
• Caregiver consent for study participation

Exclusion Criteria:

• History of allergy to the supplement or any of its components
• Prior diagnosis of Schizophrenia Spectrum and Other Psychotic Disorders according to the criteria Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) or the International Statistical Classification of Diseases and Related Health Problems (ICD-11)
• Participants having medical history of recurring urinary tract infections
• Participants having medical history of renal or liver failure
• Participants concurrently participating in other clinical studies